Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Persistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years.

Hammers CM, Chen J, Lin C, Kacir S, Siegel DL, Payne AS, Stanley JR.

J Invest Dermatol. 2015 Mar;135(3):742-9. doi: 10.1038/jid.2014.291. Epub 2014 Jul 14.

2.

Clonal analysis of B-cell response in pemphigus course: toward more effective therapies.

Di Zenzo G, Zambruno G.

J Invest Dermatol. 2015 Mar;135(3):651-4. doi: 10.1038/jid.2014.499.

3.

Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris.

Behzad M, Möbs C, Kneisel A, Möller M, Hoyer J, Hertl M, Eming R.

Br J Dermatol. 2012 Apr;166(4):844-52. doi: 10.1111/j.1365-2133.2011.10732.x.

PMID:
22092243
4.

Dissecting the anti-desmoglein autoreactive B cell repertoire in pemphigus vulgaris patients.

Qian Y, Diaz LA, Ye J, Clarke SH.

J Immunol. 2007 May 1;178(9):5982-90.

5.

Pathogenic IgG antibodies against desmoglein 3 in pemphigus vulgaris are regulated by HLA-DRB1*04:02-restricted T cells.

Eming R, Hennerici T, Bäcklund J, Feliciani C, Visconti KC, Willenborg S, Wohde J, Holmdahl R, Sønderstrup G, Hertl M.

J Immunol. 2014 Nov 1;193(9):4391-9. doi: 10.4049/jimmunol.1401081. Epub 2014 Sep 24.

6.

Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris.

Nagel A, Podstawa E, Eickmann M, Müller HH, Hertl M, Eming R.

J Invest Dermatol. 2009 Sep;129(9):2202-10. doi: 10.1038/jid.2009.27. Epub 2009 Mar 12.

7.

Synergistic pathogenic effects of combined mouse monoclonal anti-desmoglein 3 IgG antibodies on pemphigus vulgaris blister formation.

Kawasaki H, Tsunoda K, Hata T, Ishii K, Yamada T, Amagai M.

J Invest Dermatol. 2006 Dec;126(12):2621-30. Epub 2006 Jul 13.

8.

Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab).

Marzano AV, Fanoni D, Venegoni L, Berti E, Caputo R.

Dermatology. 2007;214(4):310-8.

PMID:
17460402
9.

Autoreactive T cells in the immune pathogenesis of pemphigus vulgaris.

Amber KT, Staropoli P, Shiman MI, Elgart GW, Hertl M.

Exp Dermatol. 2013 Nov;22(11):699-704. doi: 10.1111/exd.12229. Review.

PMID:
24433179
11.
12.

Genetic characterization of human Dsg3-specific B cells isolated by flow cytometry from the peripheral blood of patients with pemphigus vulgaris.

Yamagami J, Takahashi H, Ota T, Amagai M.

J Dermatol Sci. 2008 Nov;52(2):98-107. doi: 10.1016/j.jdermsci.2008.05.002. Epub 2008 Jun 30.

PMID:
18586466
13.

Rituximab exerts a dual effect in pemphigus vulgaris.

Eming R, Nagel A, Wolff-Franke S, Podstawa E, Debus D, Hertl M.

J Invest Dermatol. 2008 Dec;128(12):2850-8. doi: 10.1038/jid.2008.172. Epub 2008 Jun 19.

14.

Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy.

Feldman RJ, Christen WG, Ahmed AR.

Br J Dermatol. 2012 Mar;166(3):511-7. doi: 10.1111/j.1365-2133.2011.10658.x. Epub 2012 Jan 19.

PMID:
21967407
15.

Novel system evaluating in vivo pathogenicity of desmoglein 3-reactive T cell clones using murine pemphigus vulgaris.

Takahashi H, Amagai M, Nishikawa T, Fujii Y, Kawakami Y, Kuwana M.

J Immunol. 2008 Jul 15;181(2):1526-35.

16.

Desmoglein 1 and 3 enzyme-linked immunosorbent assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activity.

Daneshpazhooh M, Chams-Davatchi C, Khamesipour A, Mansoori P, Taheri A, Firooz A, Mortazavi H, Esmaili N, Dowlati Y.

J Eur Acad Dermatol Venereol. 2007 Nov;21(10):1319-24.

PMID:
17958835
17.

Low-dose rituximab is effective in pemphigus.

Horváth B, Huizinga J, Pas HH, Mulder AB, Jonkman MF.

Br J Dermatol. 2012 Feb;166(2):405-12. doi: 10.1111/j.1365-2133.2011.10663.x. Epub 2012 Jan 9.

PMID:
21967609
18.

Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab.

Pfütze M, Eming R, Kneisel A, Kuhlmann U, Hoyer J, Hertl M.

Dermatology. 2009;218(3):237-45. doi: 10.1159/000187431. Epub 2008 Dec 16.

PMID:
19088461
19.

Pemphigus vulgaris and its active disease mouse model.

Amagai M.

Curr Dir Autoimmun. 2008;10:167-81. doi: 10.1159/000131453. Review.

PMID:
18460885
20.

Rituximab in pemphigus foliaceous with autoantibodies against both Desmoglein 1 and Desmoglein 3.

Carvalho R, Maio P, Cunha D, Freitas I, Afonso A, Cardoso J.

Eur J Dermatol. 2011 May-Jun;21(3):415-6. doi: 10.1684/ejd.2011.1288. No abstract available.

PMID:
21527367
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk